Psyence Biomed

Psyence Group’s NASDAQ-Listed Associate, Psyence Biomedical, Announces Export of Nature-Derived Psilocybin to Australia and Provides Update on Upcoming Phase IIb Trial

Psyence Group2024-07-30T10:30:31+02:00July 30, 2024|Investor Information, Psychedelic News, Press Releases|

Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Export of Nature-Derived Psilocybin to Australia and Provides Update on Upcoming Phase IIb Trial

Psyence Group’s NASDAQ Listed Associate, Psyence Biomedical Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial

Psyence Group2024-05-06T14:54:38+02:00May 6, 2024|Press Releases, Investor Information, Psychedelic News|

Psyence Biomedical Ltd has announced that its Australian subsidiary, Psyence Australia Pty Ltd ("Psyence Australia"), has entered into a partnership with Fluence,